Logo

ZJYL

Jin Medical International Ltd.

ZJYL

Jin Medical International Ltd. • NASDAQ
$0.25 ▼ -1.45% (-0.00)
Market Cap $39.45 M
52w High $1.42
52w Low $0.21
Dividend Yield 0%
P/E 25.2
Volume 83.38K
Outstanding Shares 156.55M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $9.882M ▼ $2.987M ▼ $-89.008K ▼ -0.901% ▼ $-0.001 ▼ $-322.952K ▼
Q4-2024 $12.945M ▲ $3.403M ▲ $1.882M ▲ 14.537% ▼ $0.012 ▲ $2.527M ▲
Q2-2024 $10.557M ▲ $2.568M ▲ $1.794M ▲ 16.995% ▲ $0.011 ▲ $1.349M ▼
Q4-2023 $9.568M ▼ $2.158M ▲ $1.112M ▼ 11.62% ▼ $0.007 ▼ $1.361M ▼
Q2-2023 $10.253M $1.861M $1.766M 17.227% $0.013 $1.886M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $30.957M ▲ $48.523M ▲ $20.767M ▲ $27.913M ▼
Q4-2024 $26.757M ▲ $45.801M ▲ $17.248M ▲ $28.815M ▲
Q2-2024 $25.988M ▲ $41.16M ▲ $15.005M ▲ $26.244M ▲
Q4-2023 $16.698M ▲ $32.903M ▲ $8.924M ▲ $23.979M ▲
Q2-2023 $13.381M $31.022M $7.476M $23.547M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-89.008K ▼ $5.124M ▲ $-8.378M ▼ $9.802M ▲ $2.996M ▲ $510.896K ▲
Q4-2024 $1.882M ▲ $-1.257M ▼ $-5.365M ▼ $5.65M ▼ $-8.875M ▼ $-1.319M ▼
Q2-2024 $1.794M ▲ $49.998K ▼ $-4.149M ▼ $6.004M ▲ $972.698K ▲ $-33.682K ▼
Q4-2023 $1.112M ▼ $362.91K ▼ $-656.419K ▲ $-1.189M ▼ $-1.755M ▼ $259.987K ▼
Q2-2023 $1.766M $2.743M $-7.074M $8.1M $8.684M $2.732M

Five-Year Company Overview

Income Statement

Income Statement Revenue has been very small and essentially flat over the last few years, with decent gross margins but earnings hovering around breakeven once all costs are included. This suggests a business that is still in an early or transition phase, not yet showing clear, scalable profit growth. The slight improvement in per‑share earnings is encouraging but based on tiny absolute levels, so the underlying profit picture remains fragile and highly sensitive to any setback in sales or costs.

Balance Sheet

Balance Sheet The balance sheet looks relatively light but has been slowly building up in size, with total assets and shareholders’ equity trending upward. Debt has appeared but remains modest, while cash has stayed fairly stable, which points to a cautious use of leverage. Overall, the company does not look heavily burdened by obligations, but its financial base is still thin, meaning it has less cushion if growth plans take longer or markets become tougher.

Cash Flow

Cash Flow Operating and free cash flows have been close to flat, with no clear pattern of strong cash generation yet. The business does not seem to be burning large amounts of cash, but it also is not consistently producing meaningful surplus cash from operations. Capital spending has been very low in the reported figures, so any ramp‑up in investment for new facilities or products could change the cash profile quickly and is an important area to watch.

Competitive Edge

Competitive Edge Jin Medical operates in a crowded medical equipment and mobility market but tries to stand out through lightweight, ergonomic wheelchairs and assistive devices. Its strong presence in Japan and a sizeable patent portfolio give it some differentiation and a reputation for quality in a demanding market. Manufacturing in China supports cost competitiveness, and the joint venture for mobility scooters in China could deepen market reach. At the same time, reliance on a few key markets, intense global competition, and the company’s small scale mean its competitive position, while promising, is not yet deeply entrenched.

Innovation and R&D

Innovation and R&D Innovation is a clear focal point: the company works with academic partners, has developed ultralight electric wheelchairs with advanced features, and is investing in an intelligent manufacturing facility that uses automation and precise production techniques. Its growing patent base, including in newer areas like nanobathing products, shows active R&D and an attempt to protect its designs. Jin Medical is also extending into micro hyperbaric chambers and beauty and wellness devices, signaling a push to turn its engineering and manufacturing know‑how into a broader product ecosystem. The key uncertainty is how quickly these innovations translate into steady, profitable sales rather than remaining promising but small niches.

Summary

Jin Medical is a young, niche healthcare manufacturer that is still small in financial terms but ambitious in strategy. The income statement and cash flows suggest an early‑stage or transition business: not clearly loss‑making, but also not yet demonstrating strong, repeatable profit and cash generation. The balance sheet looks relatively clean and lightly leveraged, yet also thin, which limits room for error. On the strategic side, the company’s strengths lie in product innovation, patents, ties to Japanese customers, and low‑cost Chinese manufacturing, with new bets in wellness and beauty equipment and an automated plant in development. The main risks center on execution—scaling production, broadening markets beyond Japan, monetizing new product lines, and maintaining quality and regulatory compliance in a highly competitive global industry—so outcomes may be quite variable as the story unfolds.